Dr Nicole van der Weerden completed her PhD in Biochemistry at La Trobe University in 2007. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006. Since completing her PhD, Dr van der Weerden has worked for Hexima and has led the gene discovery program for the Pioneer partnership on control of fungal diseases in corn. She led the Hexima team that identified the clinical opportunities for plant antifungal molecules and discovered and developed pezadeftide (formerly HXP124) for treatment of onychomycosis. Dr van der Weerden is an inventor on nine patent applications.
Dr van der Weerden completed a Master of Business Administration in 2013 at Melbourne Business School and is a graduate of the Australian Institute of Company Directors. She was Hexima’s Chief Executive Officer from December 2015 until September 2020, taking on the Chief Operating Officer role from September 2020.
Dr van der Weerden has been a Director of the Company since 16 December 2014.
Latest News
Wilsons Updated Research Report
Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains its OVERWEIGHT rating and a $0.75 12-month price target. View the full report (pdf)
ShareCafe Webinar 29 April 2022
Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 29 April 2022 at 12:30pm AEST. Mr Aldridge provided a company overview and discussed its phase II clinical trial, including when the company is expecting results from the trial. This...
NailMail Q1 2022
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 March 2022. Achievements for the quarter include: Appointed Mr Philip Rose as Chief Commercial Officer and strengthened the manufacturing team with the appointment of Mr Om...